Literature DB >> 18760581

Economic burden prior to COPD diagnosis: a matched case-control study in the United States.

Manabu Akazawa1, Rachel Halpern, Aylin A Riedel, Richard H Stanford, Anand Dalal, Christopher M Blanchette.   

Abstract

BACKGROUND: In the United States, chronic obstructive pulmonary disease (COPD) diagnosis is often a lengthy process, and consequently results in delays in treatment in early stages. Disease progression and complication may result in increased levels of healthcare service use. To understand the economic burden of COPD prior to diagnosis in the U.S., trends in utilization and costs during the period before initial COPD diagnosis were compared with matched controls.
METHODS: A retrospective case-control study was conducted using medical and pharmacy claims data from a large managed care health plan representing a base population of over 30 million covered lives in the U.S. COPD patients with at least 12 months of continuous enrollment and aged 40 years or older were identified (n=28,968) and matched to up to three random controls (n=81,322) by age, gender, region of plans and index date. Multivariate regression models were used to estimate average incremental service use and cost between COPD patients and controls. Moreover, trends in utilization and costs for the COPD patients were examined over 36 months before diagnosis.
RESULTS: COPD patients used 1.5-1.6 times more inpatient/emergency department (IP/ED) services and office visits compared to control patients. The average incremental annual costs for IP/ED services, office visits, and medical and pharmacy services were estimated at $550, $238, $1438 and $401, respectively, after adjusting for age, gender, region and comorbid conditions. The 36-month trend analysis showed that COPD patients' healthcare utilization and costs increased gradually over time, often with a marked increase in the month before COPD diagnosis.
CONCLUSIONS: COPD patients in the U.S. consumed substantial healthcare services and costs prior to diagnosis. More timely diagnosis and subsequent treatment may avoid costly healthcare utilization and unnecessary mortality and morbidity post-diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18760581     DOI: 10.1016/j.rmed.2008.07.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.

Authors:  Sara M May; James T C Li
Journal:  Allergy Asthma Proc       Date:  2015 Jan-Feb       Impact factor: 2.587

Review 2.  Improving Detection of Early Chronic Obstructive Pulmonary Disease.

Authors:  Wassim W Labaki; MeiLan K Han
Journal:  Ann Am Thorac Soc       Date:  2018-12

Review 3.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

4.  Prevalence of Airflow Obstruction in U.S. Adults Aged 40-79 Years: NHANES Data 1988-1994 and 2007-2010.

Authors:  Brent Doney; Eva Hnizdo; Charles F Dillon; Ryne Paulose-Ram; Timothy Tilert; Michael Wolz; Lu-Ann Beeckman-Wagner
Journal:  COPD       Date:  2015-08       Impact factor: 2.409

5.  Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality.

Authors:  Carlos H Martinez; David M Mannino; Fabian A Jaimes; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Alejandro A Diaz
Journal:  Ann Am Thorac Soc       Date:  2015-12

6.  A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol.

Authors:  Jeremy M Bunker; Helen K Reddel; Sarah M Dennis; Sandy Middleton; Cp Van Schayck; Alan J Crockett; Iqbal Hasan; Oshana Hermiz; Sanjyot Vagholkar; Guy B Marks; Nicholas A Zwar
Journal:  Implement Sci       Date:  2012-09-07       Impact factor: 7.327

7.  Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.

Authors:  Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Mohsen Sadatsafavi; J Mark FitzGerald; Bruce McManus; Don Sin
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

Review 8.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

9.  Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation.

Authors:  Daniel E Murphy; Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-04-18

10.  Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost.

Authors:  Kyle Darnell; Alok Kumar Dwivedi; Zhouyang Weng; Ralph J Panos
Journal:  Cost Eff Resour Alloc       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.